SPA0355

Overview

SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs , Akt , and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > RANKL/RANK | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > Akt | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-169703
• CAS No.: 1251839-15-2
• Molecular Formula: C22H21N3O2S
• Molecular Weight: 391.49
• Purity: 99.54%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (12.77 mM); Clear solution
• Availability: In-stock

Source

Original product source